Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-Term Assessment of Natalizumab Therapy

J Neurol Sci; ePub 2016 Mar 16; Prosperin, et al

Publish date:: March 29, 2016

Natalizumab may ensure a higher proportion of patients achieving sustained long-term disease remission than that previously reported with self-injectable treatments (<10%). This according to a study of 152 patients with relapsing MS up to 7 years after starting natalizumab therapy. Researchers found:

• Of 152 patients, 58 were still on treatment and 94 patients discontinued treatment after a median 3 years.

• According to an intention-to-treat approach, 34% of patients maintained their No Evidence of Disease Activity (NEDA) status at the end of follow-up.

• The proportion of patients with NEDA increases to 41% after excluding from analysis 64 patients who discontinued natalizumab due to concerns about progressive multifocal leukoencephalopathy.

Citation: Prosperin L Fanelli F, Pozzilli C. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. [Published online ahead of print March 16, 2016]. J Neurol Sci. doi:10.1016/j.jns.2016.03.025.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,